Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion Denies IP Infringement Claims Made by Cellectricon

By a GenomeWeb staff reporter

NEW YORK (Genomeweb News) – Fluxion Biosciences today has denied that it is infringing patents held by Cellectricon that are at the center of an IP infringement suit that initially began in July 2009 but resumed this week.

Cellectricon has claimed that Fluxion is infringing three of its US patents as well as a fourth patent held by Gyros but licensed to Cellectricon. The patents — US Nos. 7,390,650; 7,470,518; 7,563,614; and 5,376,252 — cover microfluidic technology used in Cellectricon's ion channel drug screening solution, the Dynaflow HT System.

In the suit, which was filed in the US District Court for the Northern District of California, Cellectricon claims that Fluxion's IonFlux automated patch clamp system infringes the patents.

Gothenburg, Sweden-based Cellectricon and South San Francisco, Calif.-based Fluxion informed the court on Nov. 23, 2009 that they wished to explore a settlement "within the next 60 days."

However, Cellectricon said earlier this week that it had resumed the litigation.

In response, Fluxion CEO Jeff Jensen said yesterday that the firm would defend the lawsuit vigorously.

"Fluxion has invested considerable time and resources to develop its own intellectual property position for cell-based screening systems, and we respect the intellectual property rights of others," Jensen said. "Cellectricon's claim of patent infringement is a baseless attempt to block Fluxion's penetration and growth in the ion channel screening market."

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.